MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Natera Inc

Fermé

SecteurSoins de santé

143.08 2.35

Résumé

Variation du prix de l'action

24h

Actuel

Min

136.95

Max

146.42

Chiffres clés

By Trading Economics

Revenu

-22M

-54M

Ventes

36M

476M

BPA

-0.41

Marge bénéficiaire

-11.295

Employés

4,424

EBITDA

-27M

-46M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+40.54% upside

Dividendes

By Dow Jones

Prochains Résultats

8 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.4B

19B

Ouverture précédente

140.73

Clôture précédente

143.08

Sentiment de l'Actualité

By Acuity

25%

75%

66 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Natera Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 mai 2024, 14:49 UTC

Résultats
Actions en Tendance

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

Comparaison

Variation de prix

Natera Inc prévision

Objectif de Prix

By TipRanks

40.54% hausse

Prévisions sur 12 Mois

Moyen 197.67 USD  40.54%

Haut 251 USD

Bas 175 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

16 ratings

16

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

136.56 / 152.1Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

66 / 386Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.